Merck & Co. Inc.is studying GE Healthcare’s investigational positron emission tomography imaging agent flutemetamol as a potential companion diagnostic for its Alzheimer’s disease therapy, MK-8931, under a partnership announced Dec. 18.
The announcement comes on the heels of Merck’s Dec. 3 announcement that it started a phase II/III study of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?